REG - Aptamer Group PLC - Contract wins

AptamerAnnouncement

17/08/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230817:nRSQ5677Ja&default-theme=true

RNS Number : 5677J  Aptamer Group PLC  17 August 2023

17 August 2023

 

Aptamer Group plc

 

Contract wins

 

Aptamer Group plc (AIM: APTA), the developer of novel Optimer(®) binders
to enable innovation in the life sciences industry, today announces signing of
two new contracts with a top five pharma partner valued up to £219,000.

 

These two contracts represent further conversion of the sales pipeline
announced previously. The final value to be recognised as revenue for these
new contracts will be subject to scientific and commercial attrition as the
contracts progress, which is scheduled to be completed over the course of the
current financial year.

 

The first contract is for the development of an Optimer pair to a
neurodegenerative biomarker for use in an immunoassay platform. The second
contract is a follow-on contract for the final stage of Optimer development to
a neuronal protein target for immunohistochemistry (IHC), following positive
results in the earlier stages of Optimer development.  This builds on the
adoption of our Optimer-Fc platform for use in automated IHC workflows.

 

Optimer binders are being sought as alternatives to traditional antibodies for
analytical assays to enable increased accuracy and selectivity in the
detection of validated biomarkers, while the extended target range of Optimer
binders compared with antibodies enables the generation of reagents to novel
biomarkers.

 

Dr Rob Quinn, CEO of Aptamer Group, said: "I am pleased to be able to extend
our partnership with this top five pharma partner. These two projects are
further evidence of the need for Optimer binders to meet challenging
requirements for use in real-world applications when, to date, antibodies have
been unable to provide a satisfactory solution, such as IHC. Building
awareness and adoption of Optimer technology by such partners is key to
allowing us to deliver on our strategy of executing therapeutic, diagnostic,
and bioprocessing licensing deals."

 

 

 

- ENDS -

 

For further information, please contact:

 

 

 Aptamer Group plc                                                            +44 (0) 1904 217 404

 Dr Rob Quinn
 SPARK Advisory Partners Limited - Nominated Adviser                          +44 (0) 20 3368 3550

 Andrew Emmott / Mark Brady / Adam Dawes
 Turner Pope Investments (TPI) Limited - Broker                               +44 (0) 20 3657 0073

 James Pope
 Consilium Strategic Communications                                           +44 (0) 20 3709 5700

 Matthew Neal / Lucy Featherstone

 aptamergroup@consilium-comms.com (mailto:aptamergroup@consilium-comms.com)

 

This announcement contains inside information for the purposes of Article 7 of
Regulation (EU) No 596/2014 as it forms part of UK domestic law by virtue of
the European Union (Withdrawal) Act 2018.

About Aptamer Group plc

Aptamer (http://www.aptamergroup.com/)  develops custom affinity binders
through its proprietary Optimer(®) platform to enable new approaches in
therapeutics, diagnostics, and research applications. The Company strives to
deliver transformational solutions that meet the needs of life science
researchers and developers through the use of its proprietary Optimer
platform.

Optimer binders are oligonucleotide affinity ligands that can function as an
antibody alternative. The global affinity ligand market is currently worth
over $170 billion. Optimer binders are engineered to address many of the
issues found with alternative affinity molecules, such as antibodies, and
offer new, innovative solutions to bioprocessing, diagnostic and
pharmaceutical scientists.

Aptamer has successfully delivered projects for global pharma companies,
diagnostic development companies, and research institutes covering a range of
targets and applications with the objective of establishing royalty-bearing
licenses. Through the unique Optimer technology and processes, scientists and
collaborators can make faster, more informed decisions that support discovery
and development across the Life Sciences.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTUNRUROBUWAUR